Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus HYTONE.
ARAZLO vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid